Clinical trial
ALGRX 4975 in the Treatment of Patients With Morton's Neuroma
NCT00130962 · AlgoRx Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00130962 |
|---|---|
| Title | ALGRX 4975 in the Treatment of Patients With Morton's Neuroma |
| Official title | A Randomized, Double-Blind, Placebo-Controlled Trial of ALGRX 4975 in Subjects With Painful Intermetatarsal Neuroma |
| Lead sponsor | AlgoRx Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neuroma |
| Intervention type | Drug |
| Interventions | ALGRX 4975 |
| Enrollment | 60 |
| Start date | Sep 1, 2004 |
| Completion | Feb 1, 2006 |
| First posted | Aug 17, 2005 |
| Last update posted | Oct 3, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: